Latest News About Revolution Medicines Inc

Here are the latest publicly reported developments for Revolution Medicines Inc. RVMD, based on current press and market updates:

• Company updates and financial results: Revolution Medicines released its fourth quarter and full-year 2024 results, including a progress update on the RAS program and guidance for 2025 enrollment in ongoing trials. This reflects ongoing evaluation of the RAS(ON) program and anticipated data readouts in the near term.[3]
• Financing and partnerships: In mid-2025, Revolution Medicines announced a financing arrangement with Royalty Pharma to support its RAS(ON) pipeline, highlighting a commitment to advance daraxonrasib and related programs.[1]
• Trial status and clinical program updates: In 2025, there were reports of ongoing Phase 3 efforts for daraxonrasib in pancreatic cancer (RASolute 302 trial) with anticipated enrollment milestones and data readouts planned for 2025 or 2026 depending on site progression.[3]
• Independent news and market activity: The stock has experienced volatility with coverage from market outlets noting updates on safety/efficacy signals in preclinical and clinical contexts, as well as investor updates around clinical program milestones and potential data disclosures in 2025–2026.[2][6]

If you’d like, I can pull the most recent press release or earnings transcript and summarize key data (trial milestones, safety signals, and financials) with citations. I can also provide a quick snapshot of the current stock move and what catalysts are anticipated next.